- Trial Phase
- Phase 3
- Time to Market
- BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
- Why 7/10
- The next hard, dated catalyst is the BLA submission for cretostimogene in BCG-unresponsive NMIBC, expected to complete in Q4 2026 (~3-4 months away). This is the lead (essentially only) asset driving the company's valuation, making this a major de-risking milestone. However, a BLA submission is not the final approval binary (that comes later), so the score is 7 rather than 8-10.
Watch for BLA submission completion in Q4 2026 — this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.
Price Chart
Executive Summary
Cretostimogene grenadenorepvec is an oncolytic immunotherapy (engineered adenovirus) being developed by CG Oncology (Nasdaq: CGON) for non-muscle invasive bladder cancer (NMIBC). Phase 3 BOND-003 data published in The Lancet Oncology showed a 75.5% complete response rate with a median duration of response of 27.9 months and no Grade 3+ treatment-related adverse events in BCG-unresponsive NMIBC — a high-need setting with no approved bladder-sparing alternatives. The company plans to submit a BLA to the FDA in Q4 2026, which is the next major catalyst. Analysts are overwhelmingly bullish (19 Buy/Strong Buy vs 2 Hold, mean price target ~$91 implying ~18.6% upside), and the company holds ~$1B in cash. However, the stock carries ~12.7% short interest, recent insider selling via 10b5-1 plans, and a $1.05B ATM equity overhang that creates dilution risk.
How It Works
Cretostimogene is an oncolytic virus — a modified adenovirus designed to selectively infect and kill cancer cells while leaving healthy cells alone. It is administered directly into the bladder via a catheter (intravesical instillation). Once inside tumor cells, it replicates and causes them to burst, and it also produces GM-CSF, a protein that recruits the patient's own immune system to attack remaining cancer cells. This dual mechanism (direct tumor killing + immune activation) makes it a bladder-sparing therapy for patients who have failed standard BCG immunotherapy.
Trial Status
Phase 3 BOND-003 (Cohort C) in BCG-unresponsive NMIBC has reported positive results published in The Lancet Oncology (75.5% CR rate, median DOR 27.9 months, no Grade 3+ TRAEs). Phase 3 PIVOT-006 in intermediate-risk NMIBC (adjuvant post-TURBT) is active but no longer recruiting, with estimated primary completion June 2026 and topline data expected soon. Phase 2 CORE-008 combination data (cretostimogene + gemcitabine) showed 89.5% high-grade event-free survival at 6 months.
The Two-Sided Case
Upcoming Catalysts
- BLA submission for BCG-unresponsive NMIBC expected Q4 2026
- Phase 3 PIVOT-006 topline data (intermediate-risk NMIBC) — expected H1 2026, potentially imminent
- Potential FDA acceptance of BLA and PDUFA date assignment following submission
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CG Oncology, Inc. 424B5 CGON ·Originating report